Molecular Therapeutics Laboratory, Department of Neurological Surgery, University of California San Francisco, 1855 Folsom Street, Mission Center Building, Rm. 226, San Francisco, CA 94103, USA.
Toxins (Basel). 2011 Apr;3(4):369-97. doi: 10.3390/toxins3040369. Epub 2011 Mar 31.
Liposomes have long been effective delivery vehicles for transport of toxins to peripheral cancers. The combination of convection-enhanced delivery (CED) with liposomal toxins was originally proposed to circumvent the limited delivery of intravascular liposomes to the central nervous system (CNS) due to the blood-brain-barrier (BBB). CED offers markedly improved distribution of infused therapeutics within the CNS compared to direct injection or via drug eluting polymers, both of which depend on diffusion for parenchymal distribution. This review examines the basis for improved delivery of liposomal toxins via CED within the CNS, and discusses preclinical and clinical experience with these therapeutic techniques. How CED and liposomal technologies may influence future neurooncologic treatments are also considered.
脂质体作为一种有效的药物输送载体,长期以来一直被用于将毒素输送到外周肿瘤。最初提出将对流增强输送(CED)与脂质体毒素结合使用,是为了避免由于血脑屏障(BBB)的存在而导致血管内脂质体向中枢神经系统(CNS)的输送受限。与直接注射或通过药物洗脱聚合物给药相比,CED 可显著改善 CNS 内输注治疗药物的分布,后两者均依赖于扩散实现实质内分布。本文综述了 CED 改善 CNS 内脂质体毒素传递的基础,并讨论了这些治疗技术的临床前和临床经验。CED 和脂质体技术如何影响未来的神经肿瘤治疗也在讨论之列。